Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

BLTE

Belite Bio Inc ADR

Sep 13 • 04:00PM ET

48.82

Dollar change +0.12
Percentage change 0.25	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: SPEM EWX APIE BBC GXC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.23	Insider Own	-	Shs Outstand	29.15M	Perf Week	1.29%
Market Cap	1.49B	Forward P/E	-	EPS next Y	-0.96	Insider Trans	-	Shs Float	-	Perf Month	-2.16%
Income	-35.29M	PEG	-	EPS next Q	-0.29	Inst Own	0.83%	Short Float	-	Perf Quarter	-2.55%
Sales	0.00M	P/S	-	EPS this Y	1.85%	Inst Trans	80.50%	Short Ratio	6.37	Perf Half Y	29.12%
Book/sh	3.74	P/B	13.04	EPS next Y	17.47%	ROA	-39.40%	Short Interest	0.27M	Perf Year	58.25%
Cash/sh	3.67	P/C	13.31	EPS next 5Y	-	ROE	-41.44%	52W Range	28.51 - 50.66	Perf YTD	6.71%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-36.58%	52W High	-3.63%	Beta	-1.45
Dividend TTM	-	Quick Ratio	24.76	Sales past 5Y	0.00%	Gross Margin	-	52W Low	71.24%	ATR (14)	1.15
Dividend Ex-Date	-	Current Ratio	24.76	EPS Y/Y TTM	-	Oper. Margin	0.00%	RSI (14)	50.69	Volatility	1.80% 2.03%
Employees	20	Debt/Eq	0.00	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	56.75
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	22.17%	Payout	-	Rel Volume	0.54	Prev Close	48.70
Sales Surprise	-	EPS Surprise	-21.09%	Sales Q/Q	-	Earnings	Aug 12 AMC	Avg Volume	42.42K	Price	48.82
SMA20	-0.29%	SMA50	0.16%	SMA200	8.25%	Trades		Volume	22,934	Change	0.25%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-14-23	Initiated	Maxim Group	Buy	$60
Jul-28-23	Initiated	Cantor Fitzgerald	Overweight	$43
Jul-26-23	Initiated	SVB Securities	Outperform	$25
Aug-01-22	Initiated	H.C. Wainwright	Buy	$58
Jul-01-22	Initiated	The Benchmark Company	Buy	$57

Sep-10-24 08:00AM	Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease (GlobeNewswire)
Sep-03-24 08:00AM	Belite Bio to Participate in Three Upcoming Investor Conferences (GlobeNewswire)
Sep-01-24 08:00AM	Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer (GlobeNewswire)
Aug-09-24 09:52PM	BLTE Stock Earnings: Belite Bio Misses EPS for Q2 2024 (InvestorPlace)
04:30PM	Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
08:00AM	Loading…
Aug-08-24 08:00AM	Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference (GlobeNewswire) +5.33%
Aug-05-24 07:10PM	Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-08-24 08:00AM	Belite Bio to Present at the JonesHealthcare Seaside Summit (GlobeNewswire) +6.81%
Jun-12-24 02:55AM	Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan (GlobeNewswire)
May-14-24 08:00AM	Belite Bio to Participate in the Benchmark's 4th Annual Healthcare House Call Investor Conference (GlobeNewswire)
07:53AM	BLTE Stock Earnings: Belite Bio Misses EPS for Q1 2024 (InvestorPlace)
05:17AM	Belite Bio's Q1 Loss Narrows (MT Newswires)
May-13-24 09:50PM	Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
08:00AM	Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference (GlobeNewswire)
May-08-24 08:00AM	Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results (GlobeNewswire)
08:15AM	Loading…
May-06-24 08:15AM	Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant (GlobeNewswire)
08:00AM	Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting (GlobeNewswire)
May-01-24 04:15PM	Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting (GlobeNewswire)
Apr-26-24 06:21AM	Belite Bio Unveils Plan to Offer 651,380 American Depository Shares (MT Newswires)
Apr-25-24 07:15PM	Belite Bio Announces $25 Million Registered Direct Offering (GlobeNewswire)
Apr-10-24 09:55AM	Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect? (Zacks)
Mar-22-24 08:00AM	Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan (GlobeNewswire)
Mar-11-24 10:28PM	Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website (GlobeNewswire) -12.47%
09:27PM	Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-06-24 08:00AM	Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-04-24 08:00AM	Belite Bio to Participate in the Leerink Partners Global Biopharma Conference (GlobeNewswire)
Feb-07-24 08:00AM	Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Nov-30-23 08:00AM	Belite Bio to Participate in the Benchmark Company's Upcoming Discovery One-on-One Investor Conference (GlobeNewswire) +10.10%
Nov-20-23 08:00AM	Belite Bio to Participate in the BTIG Ophthalmology Day (GlobeNewswire)
Nov-13-23 08:15PM	Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
08:35AM	Loading…
Nov-10-23 08:35AM	Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing (GlobeNewswire)
Nov-07-23 08:00AM	Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-06-23 04:00PM	Belite Bio, Inc. to present at the Deutsche Bank ADR Virtual Investor Conference on 8 November 2023 (GlobeNewswire)
08:00AM	Belite Bio Presents Results from a 24-month, Phase 2 Study of Tinlarebant in Childhood-onset Stargardt Disease at the AAO Annual Meeting (GlobeNewswire)
Nov-01-23 08:35AM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts (GlobeNewswire) +5.04%
Oct-31-23 08:35PM	International companies to host live webcasts at Deutsche Bank's Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023 (GlobeNewswire)
Oct-27-23 08:00AM	Belite Bio Announces Presentation at the American Academy of Ophthalmology 2023 Annual Meeting (GlobeNewswire)
Aug-21-23 11:12AM	Belite Bio (BLTE) Stock Surges 72% in a Month: Here's Why (Zacks)
Aug-08-23 10:17PM	Belite Bio Reports Second Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
Aug-04-23 08:00AM	Belite Bio to Host Webcast on August 9, 2023 to Discuss Second Quarter 2023 Financial Results (GlobeNewswire) +10.63%
Jul-31-23 07:57AM	Is Belite Bio, Inc (NASDAQ:BLTE) Worth US$24.1 Based On Its Intrinsic Value? (Simply Wall St.)
Jul-27-23 05:00PM	Belite Bio Doses First Subject in Pivotal Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant for GA (GlobeNewswire) +10.37% +17.27%
Jul-24-23 06:04AM	Belite Bio Completes Enrollment in Pivotal Global Phase 3 DRAGON Trial Evaluating Oral Tinlarebant for Stargardt Disease (GlobeNewswire)
Jun-30-23 04:09PM	Why Shares of Belite Bio Soared This Week (Motley Fool)
May-31-23 12:22PM	Why Shares of Belite Bio Are Slumping Wednesday (Motley Fool) -31.09%
May-30-23 08:49PM	Belite Bio Announces Pricing of $30 Million Underwritten Public Offering of American Depositary Shares and Warrants (GlobeNewswire)
04:01PM	Belite Bio Announces Proposed Underwritten Public Offering of American Depositary Shares and Warrants (GlobeNewswire)
May-10-23 07:58PM	Belite Bio Reports First-Quarter 2023 Operational Highlights and Financial Results (GlobeNewswire)
03:33PM	Belite Bio to Host Webcast on May 11, 2023 to Discuss First Quarter 2023 Financial Results (GlobeNewswire)
May-04-23 11:09AM	Belite Bio to Host Key Opinion Leader Webinar Discussing Progression of Childhood-onset STGD1 and Relevance of the Tinlarebant 18-month Phase 2 Data (GlobeNewswire)
Apr-25-23 04:30PM	Belite Bio Presented 18-Month Interim Data from a 24-Month Phase 2 Study of Tinlarebant in Adolescent Stargardt Disease at the 2023 ARVO Meeting (GlobeNewswire)
Apr-11-23 09:00AM	Belite Bio to Host Key Opinion Leader Webinar on RBP4 Antagonist Tinlarebant in Late-Stage Development for Stargardt Disease 1 (GlobeNewswire)
Apr-08-23 09:02AM	We're Interested To See How Belite Bio (NASDAQ:BLTE) Uses Its Cash Hoard To Grow (Simply Wall St.)
Mar-31-23 07:03PM	Belite Bio Reports Full-Year 2022 Operational Highlights and Financial Results (GlobeNewswire)
12:57PM	Belite Bio to Host Webcast on April 3, 2023 to Discuss 2022 Full Year Financial Results (GlobeNewswire)
Jan-09-23 08:45AM	3 Breakout Growth Stocks to Buy for the Long Haul (Motley Fool)
Dec-08-22 05:14AM	2 Stocks Up 165% and 209% in 2022 That Could Keep Soaring in 2023 (Motley Fool)
Nov-18-22 08:00AM	Belite Bio Finalizes Phase 3 Clinical Trial Plans for Advanced Dry AMD Treatment with Tinlarebant (LBS-008) (GlobeNewswire)
Oct-20-22 08:00AM	Belite Bio to Host Key Opinion Leader Webinar on October 27, 2022 to discuss LBS-008 Interim Data (GlobeNewswire)
Oct-03-22 04:07PM	Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today (Investor's Business Daily) -13.26%
Oct-01-22 07:03PM	Belite Bio Presented 12-Month Interim Results of LBS-008 Phase 1b/2 Study in Adolescent Stargardt Disease at AAO Annual Meeting 2022 (GlobeNewswire)
Sep-23-22 08:00AM	Belite Bio Announces Late-Breaking Presentation at the American Academy of Ophthalmology 2022 Annual Meeting (GlobeNewswire) -5.08%
Sep-16-22 08:00AM	Belite Bio Receives Approval of LBS-008 Phase 3 Clinical Trial in China (GlobeNewswire) +9.17%
Aug-22-22 08:00AM	Belite Bio Initiates Pivotal Phase 3 Clinical Trial of LBS-008 in Stargardt Disease in the U.S. (GlobeNewswire) +18.92%
Aug-10-22 09:51PM	Belite Bio Reports First Half 2022 Operational Highlights and Financial Results (GlobeNewswire) +5.30%
Aug-01-22 04:10PM	Belite Bio to Host Conference Call on August 11, 2022 to Discuss First Half 2022 Financial Results (GlobeNewswire)
02:36PM	'Novel Approach For Retinal Disease Needs' Stock Belite Bio Has 70% Potential Upside According To This Analyst (Benzinga)
Jul-30-22 10:47AM	We're Hopeful That Belite Bio (NASDAQ:BLTE) Will Use Its Cash Wisely (Simply Wall St.)
Jul-19-22 04:05PM	Belite Bio Submits Investigational New Drug (IND) Application to FDA for Approval to Proceed with LBS-008 Phase 3 Clinical Trial for the Treatment of Stargardt Disease (GlobeNewswire) +5.25% -22.17%
May-12-22 04:30PM	Belite Bio Announces Partial Exercise of Over-Allotment Option in Initial Public Offering (GlobeNewswire)
May-05-22 08:00AM	Belite Bio Presented Interim Results of LBS-008 Phase 1b/2 Study in Adolescent STGD1 at ARVO Annual Meeting 2022 (GlobeNewswire) +15.16%
May-03-22 04:30PM	Belite Bio Announces Closing of $36 Million Initial Public Offering (GlobeNewswire) +30.78% +13.71%
06:50AM	Belite Bio Receives FDA Fast Track Designation For LBS-008 (GlobeNewswire)

Belite Bio, Inc. is a biopharmaceutical company engaged in the research and development of drugs. Its focus is on the treatment of eye diseases involving retinal degeneration such as atrophic age-related macular degeneration and autosomal recessive Stargardt disease. It also caters to metabolic diseases such as non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout. The company was founded by Yu-Hsin Lin on March 27, 2018 and is headquartered in San Diego, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	SEC Form 4
Wan Shan Chen	affiliate	Sep 04 '24	Proposed Sale	48.10	6,650	319,865	Sep 04 12:29 PM
Nathan Mata	affiliate	Aug 16 '24	Proposed Sale	500.00	30,000	15,000,000	Aug 16 06:24 PM
Hao-Yuan Chuang	Officer, Director	Aug 14 '24	Proposed Sale	49.32	100,000	4,932,000	Aug 14 04:32 PM
Yu-Hsin Lin	CEO, Chairman	Aug 14 '24	Proposed Sale	49.32	100,000	4,932,000	Aug 14 04:30 PM
Chiu, Ching Chen	affiliate	Aug 14 '24	Proposed Sale	49.84	34,568	1,722,869	Aug 14 02:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

BLTE

Belite Bio Inc ADR

Upgrade your FINVIZ experience